BioCentury
ARTICLE | Clinical News

rNAPc2: Phase IIa data

September 11, 2006 7:00 AM UTC

Data from the U.S. and Canadian Phase II ANTHEM/TIMI 32 study in 255 patients showed no significant increase in major/minor bleeding with rNAPc2 treatment vs. placebo (3.7% vs. 2.5%). The compound did...